The biotech platform to
ultimately cure mental
health disorders.

Christian Angermayer

Founder

Strategy and investor relations

• Serial entrepreneur and investor
• Co-founder, Ribopharma (RNAi translation, today Alnylam, $10bn market cap)
• Raised $1.5bn+ over the last 20 years for portfolio companies
• Invests across the entire lifecycle of a company and has been involved in more than 40 successful IPOs and M&As

Lars Wilde

Co-Founder

Advising on drug discovery and compound sourcing

• COO and Co-founder, COMPASS Pathways
• Former Co-founder and MD, Springlane
• Prior experience with Waterland Private Equity, global IVF clinics group, Boston Consulting Group
• Background: Finance and management

The Eight Most Significant Factors Contributing to Today’s Depression Epidemic (sources)

1. https://www.who.int/news-room/fact-sheets/detail/depression
2. https://www.ncbi.nlm.nih.gov/pubmed/28027366
3. https://www.who.int/mental_health/in_the_workplace
4. https://ada.com/signs-of-depression
5. https://www.nimh.nih.gov/health/statistics/suicide.shtml
6. https://adaa.org/about-adaa/press-room/facts-statistics
7. https://www.nimh.nih.gov/health/statistics/major-depression.shtml
8. https://www.bcbs.com/the-health-of-america/reports/major-depression-the-impact-overall-health
9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579396
10. https://www.ncbi.nlm.nih.gov/pubmed/26651008
11. https://www.ncbi.nlm.nih.gov/pubmed/15271581
12. https://www.ncbi.nlm.nih.gov/pubmed/24269030
13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889685
14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006295
15. https://www.ncbi.nlm.nih.gov/pubmed/11691695
16. https://www.ncbi.nlm.nih.gov/pubmed/10431682
17. https://www.ncbi.nlm.nih.gov/pubmed/19434623
18. https://pediatrics.aappublications.org/content/138/6/e20161878
19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738337
20. https://www.cdc.gov/drugoverdose/data/statedeaths.html
21. http://www.annfammed.org/content/14/1/54
22. https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
23. https://www.psychiatrictimes.com/special-reports/opioid-use-elderly
24. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2682878
25. https://jamanetwork.com/journals/jama/fullarticle/2684607
26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841310
27. https://psycnet.apa.org/record/2008-07755-000
28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021390
29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225959
30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775138
31. https://jech.bmj.com/content/68/2/110.abstract
32. https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health/index.shtml
33. https://adaa.org/serious-chronic-or-terminal-illnesses
34. https://www.ncbi.nlm.nih.gov/pubmed/30844397
35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308579/
36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017546/
37. http://www.pointinstitute.org/wp-content/uploads/2012/10/standard_v_9.2_hpa_axis.pdf
38. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860380/
39. https://www.sciencedirect.com/science/article/pii/S0747563216302552?via%3Dihub
40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633215/

Florian Brand

Co-Founder and Chief Executive Officer

Executing drug development and operations

• Interim CEO, Perception Neuroscience
• Former Co-founder and MD, Springlane
• Prior experience with Rocket Internet, Allianz, Tanzanian German Program to Support Health
• Background: Economics and management

Simon Seibold

Associate

Investments and business development

• Founder of AI-based application with neural network approach
• Experience in venture capital with focus on digital health and therapeutics
• Background: Psychology, medicine and management

Philipp Schreiber

Associate

Drug discovery and compound sourcing

• Portfolio development, Apeiron Investment Group
• Experience in M&A transactions, venture capital and strategic management
• Background: Management, entrepreneurship and business law

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

• using psychedelic compounds in therapy could provide an opportunity to significantly advance psychiatry
• treatment solutions should be as convenient, cost-effective and fast as possible
• clinical evidence has to meet the highest scientific standards
• fully integrated mental health solutions are the future

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

• technology can be used to accelerate the identification and incubation of drug candidates and compounds
• AI and big data will improve clinical trial design, comparison and decision-making
• AI has a leading role in developing personalized therapeutics
• predictive analytics through unified machine learning models help us to predict the toxicity of drugs and the efficacy of combination therapeutics

Matthias Luz, MD

Chief Medical Officer

Developing clinical strategy for lead compounds

• 26+ years of experience in various leadership roles in the biopharmaceutical industry
• Broad experience in various disease areas (e.g. CNS and cardiovascular)
• Background: Board-certified anesthesiologist and researcher in Heidelberg and Harvard

Srinivas Rao, MD, PhD

Chief Scientific Officer

Advance the science into clinical evaluation

• 20+ years of experience in various CSO and CMO leadership roles
• Deep experience in IT
• Background: MS in computer engineering and MD and PhD in Neuropharmacology (Yale-trained)

Danny Talati

Lead, Business Development

Compound sourcing and evaluating

• 6+ years of neuroscience and neurology medical experience, Eli Lilly
• Prior experience in biotech business development and consulting
• Background: Pharmacy and management

Allan Malievsky

Associate

Communications and Business Development

• Led membership development at DC-based nonprofit working on advanced illness care issues and Medicare payment reform
• Experience in fundraising and communications for thought leaders
• Background: Economics, international affairs, and healthcare policy

Greg Bates

Lead, Regulatory Affairs

Successful product approval

• 32 years in international pharmaceutical industry
• Extensive experience in international regulatory affairs encompassing drug regulation, biologics and live biotherapeutic products
• Background: Veterinary

Aaron Weaver

Senior Legal Counsel

• Coming soon!

Ana Zarzosa

Team and Research Assistant

Supporting smooth communication and a high-performance team environment

• 10+ years of experience in Yoga and Mindfulness
• 7 years of Scientific Research in Life Sciences (Dr.rer.nat)
• Prior experience in team management, company organization and healthcare industry
• Background: Nutrition, genetics, molecular & cell biology

Ali Mahomed

Global Venture Development

Operationally growing portfolio companies

• Previously at COMPASS Pathways
• Internship experience in mergers & acquisitions and private equity
• Background: Statistics and finance

Sources: The Eight Most Significant Factors Contributing to Today’s Depression Epidemic (full series)

1. https://www.who.int/news-room/fact-sheets/detail/depression
2. https://www.ncbi.nlm.nih.gov/pubmed/28027366
3. https://www.who.int/mental_health/in_the_workplace
4. https://ada.com/signs-of-depression
5. https://www.nimh.nih.gov/health/statistics/suicide.shtml
6. https://adaa.org/about-adaa/press-room/facts-statistics
7. https://www.nimh.nih.gov/health/statistics/major-depression.shtml
8. https://www.bcbs.com/the-health-of-america/reports/major-depression-the-impact-overall-health
9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579396
10. https://www.ncbi.nlm.nih.gov/pubmed/26651008
11. https://www.ncbi.nlm.nih.gov/pubmed/15271581
12. https://www.ncbi.nlm.nih.gov/pubmed/24269030
13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889685
14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006295
15. https://www.ncbi.nlm.nih.gov/pubmed/11691695
16. https://www.ncbi.nlm.nih.gov/pubmed/10431682
17. https://www.ncbi.nlm.nih.gov/pubmed/19434623
18. https://pediatrics.aappublications.org/content/138/6/e20161878
19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738337
20. https://www.cdc.gov/drugoverdose/data/statedeaths.html
21. http://www.annfammed.org/content/14/1/54
22. https://www.drugabuse.gov/publications/drugfacts/prescription-opioids
23. https://www.psychiatrictimes.com/special-reports/opioid-use-elderly
24. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2682878
25. https://jamanetwork.com/journals/jama/fullarticle/2684607
26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841310
27. https://psycnet.apa.org/record/2008-07755-000
28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021390
29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225959
30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775138
31. https://jech.bmj.com/content/68/2/110.abstract
32. https://www.nimh.nih.gov/health/publications/chronic-illness-mental-health/index.shtml
33. https://adaa.org/serious-chronic-or-terminal-illnesses
34. https://www.ncbi.nlm.nih.gov/pubmed/30844397
35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308579/
36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017546/
37. http://www.pointinstitute.org/wp-content/uploads/2012/10/standard_v_9.2_hpa_axis.pdf
38. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860380/
39. https://www.sciencedirect.com/science/article/pii/S0747563216302552?via%3Dihub
40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633215/

Ali Mahomed

Global Venture Development Junior Associate

Operationally growing portfolio companies

• Previously at COMPASS Pathways
• Internship experience in mergers & acquisitions and private equity
• Background: Statistics and finance